EFSCE
TGTX icon

Enterprise Financial Services Corp (EFSC)’s TG Therapeutics TGTX Stock Holding History

Enterprise Financial Services Corp (EFSC)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-96
Closed -$1K – 1043
2016
Q1 		$1K Buy
+96
New +$840 ﹤0.01% 998

Other funds holding TGTX

BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Enterprise Financial Services Corp (EFSC)'s TGTX Position: Q2 2016 in Review

Enterprise Financial Services Corp (EFSC) sold out of TG Therapeutics (TGTX) in Q2 2016, closing a stake of 96 shares — an estimated $1K sold.

Enterprise Financial Services Corp (EFSC) first reported a position in TGTX in Q1 2016 and held it in 1 quarter. The position peaked at $1K in Q1 2016. 91 funds tracked by Wall St. Rank hold TGTX as of Q2 2016.

  • Enterprise Financial Services Corp (EFSC) reported no remaining TG Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Enterprise Financial Services Corp (EFSC) sold 96 TG Therapeutics shares in Q2 2016, an estimated $1K.
  • Enterprise Financial Services Corp (EFSC) first reported a position in TG Therapeutics in Q1 2016 and held it in 1 quarter.
  • Enterprise Financial Services Corp (EFSC)'s TG Therapeutics position peaked at $1K in Q1 2016.
  • 91 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2016.

Based on Enterprise Financial Services Corp (EFSC)'s 13F filing for Q2 2016, filed 29 Jul 2016.